

D<sup>3</sup>  
concl

--11. (Amended) The sterile pharmaceutical suspension according to claim 8, wherein the concentration of the glucocorticosteroid or ester, acetal, or salt thereof, ranges from about 0.05 to about 20 mg/ml in the formulation.--

---

D<sup>4</sup>

--39. (Amended) A pharmaceutically acceptable inhalation powder in the form of finely divided particles having a mass median diameter (MMD) of less than 10  $\mu\text{m}$ , said particles being sterilized by heat treatment at a temperature of from 100°C to 130°C and comprising a glucocorticosteroid or ester, acetal, or salt thereof, wherein the glucocorticosteroid or ester, acetal, or salt thereof, comprises an asymmetric acetal structure.--

---

D<sup>5</sup>

--50. (Amended) A sterile pharmaceutical formulation comprising a pharmaceutically acceptable powder in the form of heat sterilized finely divided particles and comprising budesonide, rofleponide or rofleponide palmitate, or ester, acetal or salt thereof.--

---